Center for Drug Discovery conducts multidisciplinary research aimed at the discovery of new therapeutic medications
Recent Publications
December 18, 2017
Nature 547, 468–471 (27 July 2017) The cannabinoid receptor 1 (CB1) is the principal target of the psychoactive constituent of marijuana, the partial agonist Δ9-tetrahydrocannabinol (Δ9-THC)1. […]
December 18, 2017
Cell – Volume 167, Issue 3, p750–762.e14, 20 October 2016 Cannabinoid receptor 1 (CB1) is the principal target of Δ9-tetrahydrocannabinol (THC), a psychoactive chemical from Cannabis […]
About Center for Drug Discovery
The CDD was founded in 2003 and is directed by Alexandros Makriyannis, the Behrakis Chair in Pharmaceutical Biotechnology. The CDD is directed to:
- Develop novel methodologies to improve drug discovery
- Discover new medications to satisfy important medical needs
- Train students and post-doctoral fellows in the art and science of drug discovery
- Collaborate intensively with the biotechnology and pharmaceutical industries as well as leading clinical centers
